苄基四氢巴马汀对心室肌动作电位和延迟整流钾电流的频率依赖性作用

目的　研究BTHP对豚鼠乳头状肌动作电位及单个心室肌细胞延迟整流钾电流影响的频率依赖性。方法　用标准微电极方法在不同基础周长 (BCL)时测定动作电位 ;采用全细胞膜片钳技术测定延迟整流钾电流 (IK:IKr、IKs)。结果　 10 0 μmol·L-1BTHP在BCL为 :2 0 0 0、2 5 0ms时 ,使APD2 0 分别延长 11 35 %和 2 5 5 5 % ;使APD90 分别延长15 97%和 32 5 6 %。 30 μmol·L-1BTHP在刺激频率为 :0 2 5和 2 0Hz时分别使Ikr,tial从 (0 94± 0 .44 ) pA·pF-1和(0 92± 0 31) pA·pF-1降至 (0 6 0± 0 32 ) pA·pF-1和 (0 43± 0 18)pA·pF-1。在刺激频率为 :0 1和 2 0Hz时分别使Iks,tial从 (4 2 2± 0 5 6 ) pA·pF-1和 (5 14± 0 2 8)降至 (2 5 8±0 41)pA·pF-1和 (2 6 2± 0 37)pA·pF-1。结论　BTHP可频率依赖性地阻滞IKr、IKs,其延长动作电位也呈频率依赖性     

盐酸非洛普对豚鼠心室肌细胞延迟整流钾电流的抑制作用

目的　已知盐酸非洛普〔1 (2 ,6 二甲基苯氧基 ) 2 (3,4 二甲氧基苯乙氨基 )丙烷盐酸盐 ,DDPH〕对心肌钙电流和钠电流具有抑制作用 ,为全面了解其抗心律失常作用的离子机理 ,研究其对延迟整流钾电流的影响。方法　全细胞膜片钳技术记录豚鼠心室肌细胞快激活的延迟整流钾电流的尾电流(IKr tail)和慢激活的延迟整流钾电流 (IKs)及其尾电流 (IKs tail)。结果　DDPH(1～ 10 0 μmol·L- 1)浓度依赖性地抑制IKr tail,其IC50 为 7.0 (95 %可信限为4 .2 3～ 9.76 ) μmol·L- 1;DDPH 10 μmol·L- 1对IKr tail具有电压依赖性抑制作用。DDPH 10 ,30和 10 0 μmol·L- 1可浓度依赖性地抑制IKs及其IKs tail,使IKs从给药前的 (9.1± 0 .7)pA·pF- 1分别降至 (7.7± 1.7) ,(7.5± 1.8)和 (5 .6± 1.8)pA·pF- 1(P <0 .0 1) ;使IKs tail从给药前的 (1.4± 0 .2 )pA·pF- 1分别降至(1.1± 0 .2 ) ,(0 .9± 0 .2 )和 (0 .6± 0 .2 )pA·pF- 1(P <0 .0 5或P <0 .0 1) ;DDPH 30 μmol·L- 1对IKs tail具有电压依赖性抑制作用。结论　DDPH对豚鼠心室肌细胞延迟整钾电流具有抑制作用。     

苄基四氢巴马汀对大鼠心室肌细胞瞬时外向钾电流的影响

利用全细胞膜片钳技术测定大鼠心室肌细胞的Ito,研究苄基四氢巴马汀 (BTHP)对大鼠心室肌瞬时外向钾电流 (Ito)的影响 .结果显示 ,5 .0 μmol·L- 1BTHP可以降低Ito,使Ito幅值从 (13.8± 2 .2 )pA·pF- 1降至 (5 .1± 1.4 )pA·pF- 1(P <0 .0 1) .在 1～ 10 0μmol·L- 1范围内BTHP的作用呈浓度依赖性 ,IC50 为3.6μmol·L- 1,该药不改变Ito电流 电压曲线的形状 ,而使电流幅值减少 .5 .0 μmol·L- 1BTHP使稳态激活曲线右移 ,半激活电压 (V1/2 )从 (- 6.8±0 .2 )mV移至 (- 1.5± 0 .1)mV ,但曲线斜率基本不变 .BTHP对失活曲线影响不大 ,5 .0 μmol·L- 1BTHP使通道失活后恢复时间常数从 (75± 19)ms延长为(119± 2 1)ms(P <0 .0 1) .结果说明 ,BTHP浓度依赖地阻滞大鼠心室肌细胞的Ito.     

苄基四氢巴马汀和甲氧胺对豚鼠心室肌细胞延迟整流钾电流阻滞作用

目的研究苄基四氢巴马汀 (BTHP)和甲氧胺对豚鼠心室肌细胞上延迟整流钾电流作用。方法采用全细胞膜片钳技术测定延迟整流钾电流 (Ik)。结果甲氧胺 5 0 μmol·L- 1 在 37℃时可以分别使IK和IK ,tial从 (12 4± 1 8)pApF- 1 和 (4 2±0 5 )pApF- 1 上升至 (2 0 5± 0 7)pApF- 1 和 (7 2± 0 6 )pApF- 1 。若事先甲氧胺 5 0 μmol·L- 1 后 ,再加入BTHP 30 μmol·L- 1 可使BTHP阻滞IK和IK ,tial百分率分别从单独使用BTHP时的 37 5 %± 6 0 %和 35 9± 5 5 %上升到 6 2 9%± 4 3%和 6 1 1%±3 7%。结论苄基四氢巴马汀可以逆转甲氧胺对豚鼠心室肌细胞上IK 的增加作用。     

苄基四氢巴马汀对豚鼠心室肌细胞慢激活延迟整流钾电流及其尾电流的作用(英文)

目的　研究苄基四氢巴马汀 (BTHP)的抗心律失常机理。方法　采用全细胞膜片钳技术记录心室肌细胞慢激活延迟整流钾电流 (IKs)及其尾电流(IKs ,tail)。结果　BTHP在 1～ 10 0 μmol·L- 1的范围内以浓度依赖性、电压依赖性和频率依赖性方式阻滞IKs ,tail,其IC50 为 9.3μmol·L- 1(95 %可信限 :7.8～11.8μmol·L- 1)。BTHP 30 μmol·L- 1可使IKs 及IKs,tail分别降低 (40± 6 ) %和 (39± 5 ) % (P <0 .0 1)。BTHP可以抑制IKs ,tail。该药主要使IKs ,tail的失活时间常数缩短 ,从而使IKs ,tail 失活速度增加 ,而对IKs,tail的激活动力学影响不大。结论　BTHP对IKs有明显的抑制作用。     

冬虫夏草水提液对单个心室肌细胞钾通道的影响

目的　观察冬虫夏草水提液对豚鼠及大鼠心室肌细胞钾通道的作用 ,探讨冬虫夏草的抗心律失常作用机制。方法　应用全细胞膜片钳技术记录冬虫夏草水提物对豚鼠单个心室肌细胞内向整流钾电流 (IK1)、延迟整流钾电流 (IK)及大鼠心室肌细胞瞬时外向钾电流 (Ito)的影响。结果　应用 0 1g·L-1(生药浓度 )冬虫夏草水提液使豚鼠单个心室肌细胞内向整流钾电流在实验电压 - 12 0mV时从给药前(- 36 37± 5 15 ) pA/pF减少到 (- 2 9 70± 5 90 ) pA/ pF(n=5 ,P <0 0 5 ) ;延迟整流钾电流在实验电压 +70mV时 ,从给药前 (9 2 1± 2 4 2 ) pA/ pF增加至 (11 5 4± 2 98)pA/ pF(n =6 ,P <0 0 1) ;使大鼠心室肌细胞瞬时外向钾电流 (Ito)在实验电压 +5 0mV时 ,从给药前 (13 36± 0 88) pA/ pF增加至 (16 4 8± 1 0 9) (n =4 ,P <0 0 1)。结论　冬虫夏草抗心律失常作用与它对心肌细胞钾通道的作用有关。它增加IK,Ito的同时抑制IK1,将会使动作电位时程缩短而不至于发生早后除极和迟后除极     

苄基四氢巴马汀对豚鼠心室肌细胞钾电流及钙、钠电流的作用──谨以此文献给尊敬的老师江明性教授80寿辰

目的:研究苄基四氢巴马汀(BTHP)对心肌细胞的作用特点,以探讨其抗心律失常机制。方法:用全细胞膜片钳技术考察BTHP对心室肌细胞钾电流及钙、钠电流的作用。结果:BTHP30μmol·L-1明显阻滞延迟整流钾电流(IK包括:IKr及IKs)。可使IKr及IKr,tail的幅值下降,且对IKr阻滞作用呈频率依赖性;对IKs及IKs,tail幅值也有明显的抑制作用。BTHP200μmol·L-1可明显阻滞ICa,L,使其电流幅值降低,但对IK1,ICa,T,INa电流均无影响。结论:BTHP可明显阻滞心室肌细胞IKr,IKs,ICa,L电流,且对IKr阻滞作用呈频率依赖性。     

环维黄杨星D延长大鼠心室肌细胞APD作用的分子机制研究

目的　研究环维黄杨星D对分离的大鼠心室肌细胞内向整流钾电流 (IK1 )、瞬时外向钾电流 (Ito)、L 型钙电流(ICa L)和动作电位时程 (APD)的影响。方法　采用全细胞膜片钳技术记录大鼠心室肌细胞IK1 、Ito、ICa L 和APD。结果　 1和10 μmol·L- 1 环维黄杨星D明显延长分离大鼠心室肌细胞APD50 和APD90 ,10 μmol·L- 1 可明显降低静息膜电位 (RP)。环维黄杨星D对IK1 内向电流和外向电流均有明显抑制作用 ,当指令电压为 - 10 0mV时 ,1和 10 μmol·L- 1 环维黄杨星D分别使IK1 电流密度从给药前的 ( - 8.0± 1.1)pA pF降至 ( - 4 .1± 0 .7)pA pF和 ( - 3.4± 0 .8)pA pF ;当指令电压 - 30mV时 ,分别使IK1 电流密度从 ( 1.10± 0 .2 4 )pA pF降至 ( 0 .6 1± 0 .18)pA pF和 ( 0 .36± 0 .11)pA pF ;在钳制电位从 0到 + 6 0mV之间 ,环维黄杨星D明显抑制Ito,当指令电压 4 0mV时 ,1和 10 μmol·L- 1 环维黄杨星D分别使Ito电流密度从给药前的 ( 8.9± 2 .0 )pA pF降至 ( 5 .5± 1.2 )pA pF和 ( 4 .9± 0 .9)pA pF。环维黄杨星D浓度依赖性抑制ICa L,在指令电压为 10mV时 ,1和 10 μmol·L- 1 分别使ICa L电流密度从给药前的 ( - 9.9± 1.8)pA pF降至 ( - 6 .4± 1.4 )pA pF和 ( - 4 .2± 0 .6 )pA pF。结论　环     

苄基四氢巴马汀细胞内用药对豚鼠乳头状肌动作电位和心室肌细胞延迟整流钾电流的作用

目的　研究将苄基四氢巴马汀(BTHP)导入细胞内对豚鼠乳头状肌动作电位及单个心室肌细胞延迟整流钾电流的影响。方法　利用外加电压脉冲将药物导入乳头状肌细胞内，并用标准微电极方法测定动作电位；利用浓度差扩散方式使药物进入单个心室肌细胞内，采用全细胞膜片钳技术记录延迟整流钾电流（I_K）。结果　100 μmol.L^-1 BTHP使APD₂₀和APD₉₀分别延长13.5%和20.5%。30 μmol.L^-1 BTHP使I_K和I_K,tail分别从（14.1±2.2) pA.pF^-1和(4.0±0.6) pA.pF^-1降至(9.4±1.3) pA.pF^-1和(2.1±1.0) pA.pF^-1，下降率分别为33.2%和35.3%。 该药使I_K和I_K,tail的I-V曲线幅度降低，对曲线形状影响不明显。结论　BTHP入细胞内后可阻滞延迟整流钾电流和延长动作电位时程。     

一种筛选抗心律失常药物新模型的建立

目的　建立一种细胞水平的心律失常模型 ,以用于抗心律失常药物的筛选和评价。方法　酶解法分离单个大鼠心室肌细胞 ,在细胞水平给予传统诱发心律失常药物乌头碱 ,应用膜片钳技术观察记录应用乌头碱后心肌动作电位时程 (APD)、钠电流 (INa)、L 型钙电流 (ICa L)、内向整流钾电流(IK1)及瞬时外向钾电流 (Ito)的变化。结果　应用乌头碱 1μmol·L-1使大鼠单个心室肌细胞 90 %复极化动作电位时程(APD90 )从给药前的 ( 15 0 2 3± 7 0 2 )ms延长至 ( 2 3 6 0 3±2 3 2 2 )ms(n =8,P <0 0 1)。应用奎尼丁 10 μmol·L-1后动作电位时程延长与乌头碱组比较 ,APD90 进一步延长 (n =6,P <0 0 5 ) ,但应用维拉帕米 10 μmol·L-1后被乌头碱延长的APD恢复近于正常 ,在乌头碱的作用下 ,除极电压为 0mV时ICa L从 ( 72 7 9± 178 0 ) pA增加至 ( 10 82 1± 2 2 2 2 ) pA(n =6,P <0 0 1) ;钠电流 (INa)在 - 5 0mV刺激电压下从( 2 5 4± 5 5 3 ) pA增加至 ( 45 3 0 2± 475 1) pA(n =4,P <0 0 5 ) ;IK1在 - 12 0mV的刺激电压下 ,Ik1的内向成分从( 2 0 0 7 1± 3 5 9 3 ) pA增加至 ( 2 3 17 7± 40 1 8)pA(n =10 ,P <0 0 1) ;奎尼丁、维拉帕米对乌头碱诱发的钠电流和钙电流增加有抑制的作用。结论　乌头碱使?     

TOXIC AND CARCINOGENIC EFFECTS OF PARENTERAL AND PERCUTANEOUS ATP AND ITS IRON COMPLEX

ABSTRACT

The long term effects of percutaneous, subcutaneous and intraperitoneal administration of sodium–ATP (NaATP) and ferric iron–ATP (FeATP) were studied on an animal model. Both compounds induce a generalized lymphoadenitis which in the case of FeATP led to lymphomas. The analytical study of the involved target tissues showed intracellular composition changes that result from the impairment of the cell membrane permeability. The morbidity and mortality rate were higher with FeATP which seems to be the result of two different, in intensity and duration, interactions with the cell plasma membrane. The influence of the changes in cellular calcium homeostasis, and its relationship with carcinogenesis and immuno response are discussed.     

苦参碱及氧化苦参碱的药代动力学与药效动力学

以QTc延长率为效应指标,用药代动力学-药效动力学结合模型对苦参碱、氧化苦参碱iv后在免体内的处置和效应动力学作定量分析,两药的血浓时程均符合二房室模型,两药的效应与效应室浓度之间的关系均符合S形E_max模型。两药彼此的药动学和药效学性质均有明显差异,但它们各自的劳动学和药效学性质在所用剂量范围内均为非剂量依赖性。     

LIVER ALCOHOL AND ALDEHYDE DEHYDROGENASE: INHIBITION AND POTENTIATION BY HISTAMINE AGONISTS AND ANTAGONISTS

1. The in vitro effects of histamine, some other Hi- and H₂-receptor agonists and some antagonists were studied on the specific activities and kinetics of rat liver alcohol dehydrogenase (ADH), and cytoplasmic and mitochondrial liver aldehyde dehydrogenase (ALDH). 2. Histamine (H₁- and H₂-agonist) non-competitively inhibited ADH and ALDH, 2-(2-aminoethyl) pyridine (Hi-receptor agonist) non-competitively inhibited ADH. There were no changes of cytoplasmic and mitochondrial liver ALDH activities in the presence of 2-(2-aminoethyl) pyridine. 3. Betazole (H₂-receptor agonist) produced a competitive inhibition of mitochondrial ALDH but not of ADH or cytoplasmic ALDH. 4. Diphenhydramine (H₁-receptor antagonist) non-competitively inhibited ADH at a lower concentration. It stimulated mitochondrial ALDH activity without changes in cytoplasmic ALDH from control values. 5. Burimamide (H₂-receptor antagonist) produced a biphasic and dose-dependent stimulation and non-competitive inhibition of ADH and it non-competitively inhibited ALDH in both cytoplasmic and mitochondrial fractions. Metiamide (H₂-receptor antagonist) non-competitively inhibited all ADH and ALDH of both liver fraction studied. 6. It is concluded that liver ADH and ALDH activity can be altered by compounds which affect both Hi- and H₂-histamine receptors and that these compounds may cause an in vivo potentiation and/or reduction of the toxic effect of ethanol.     

HPLC和~1HNMR分析确定cis－A－和cis－B－羟甲芬太尼的组成和构型

羟甲芬太尼（１）是一个强效的镇痛剂和高亲和、高选择性的阿片μ受体激动剂。通过ＨＰＬＣ和１ＨＮＭＲ分析，ｃｉｓ－Ａ－ｌ被确定为由等量的ｃｉｓ－（＋）－（３Ｒ，４Ｓ，２＇Ｓ）－ｌ和：ｃｉｓ－（—）－（３Ｓ，４Ｒ，２＇Ｒ）－１组成的外消旋体，ｃｉｓ－Ｂ－ｌ被确定为由等量的ｃｉｓ－（—）－（３Ｒ，４Ｓ，２＇Ｒ）－１和ｃｉｓ－（＋）－（３Ｓ，４Ｒ，２＇Ｓ）－１组成的外消旋体。     

TOXICOKINETICS AND EFFECTS OF FIBROUS AND NONFIBROUS PARTICLES

Chronic inhalation of fibrous and nonfibrous particles by rats at high concentrations results in lung tumor formation if the particles are poorly soluble in the lung. Even rather benign nonfibrous particles such as TiO 2 produce this result. One significant change during a chronic inhalation exposure of poorly soluble particles of low cytotoxicity (PSP) is an impairment of normal clearance mechanisms in the alveolar region of the lung in rats, resulting in a continued buildup to high lung burdens accompanied by chronic alveolar inflammation, fibrosis, and mutational events. Since these are obviously high-dose effects, questions about their extrapolation to humans exposed to much lower concentrations have been raised. Results of key studies reported for chronic inhalation of PSP in rats indicate that mechanisms of PSP-induced lung tumors at high doses do not operate at low dose levels. Furthermore, the existence of two thresholds can be postulated: One is a dosimetric threshold for the endpoint alveolar macrophage-mediated clearance, which is related to lung particle overload. The other is a mechanistic threshold for the endpoint mutation, which is determined by the level of antioxidant defenses to counter-balance reactive oxidant species released by activated inflammatory cells. A no-observed-adverse-effect level (NOAEL) could therefore be based on avoiding alteration of the toxicokinetic of the particles such that the lung burdens stay below the dosimetric threshold. The suggestion that PSP-associated organic compounds (e.g., diesel particulate matter) contribute to the lung tumor responses in rats observed in chronic inhalation studies is not supported by experimental data from in vivo studies. It can be concluded that high-dose rat lung tumors due to PSP should not be used for low-dose extrapolations, and no significant contribution to human lung cancer risk can be predicted from levels of PSP below lung overload. With respect to the pulmonary toxicokinetics of inhaled fibrous particles, the biopersistence of long fibers (>20 µm) which cannot be phagocytized by alveolar macrophages is a key parameter related to long-term carcinogenic effects. Long fibers with a very low biopersistence should not be considered as carcinogenic. Since the clearance kinetics of fibers can generally be described by a biphasic or multiphasic pattern - fast initial and slow final phase - it is essential that the slow phase of the retention kinetics of fibers longer than 20 µm is considered in a biopersistence assay. Based on the results of such assay, fibers can be classified into one of two categories: a biopersistent fiber that cannot be dissolved in the lung within an acceptable time period; or a biosoluble fiber when even long nonphagocytizable fibers will be disappearing rapidly from the lung. However, in addition to biopersistence, it should be mandatory to evaluate fiber toxicity in an appropriate assay relative to a fiber whose long-term effects are well known. Moreover, for organic fibers it is likely that different rules may have to be established for characterization of their toxic and carcinogenic potential.     

珍珠母贝中糖胺聚糖的提取分离纯化

目的:对马氏珍珠母贝中提取、分离得到的糖胺聚糖(glycosam inog lycans,GAG)进行化学组分研究。方法:样品经还原、水解和乙酰化,采用气相色谱-质谱法定性测定。结果:测定出马氏珍珠母贝中经提取、分离得到的GAG中的3种主要成分,其骨架结构分别与(硫酸乙酰)肝素、(硫酸)软骨素和透明质酸相符。结论:马氏珍珠母贝中提取分离的糖胺聚糖中含有肝素、软骨素和透明质酸。     

SODIUM AND NORADRENALINE IN CEREBROSPINAL FLUID AND BLOOD IN SALT-SENSITIVE AND NON-SALT-SENSITIVE ESSENTIAL HYPERTENSION

1. The effects of dietary sodium on blood pressure and levels of sodium, other electrolytes and noradrenaline (NA) in the cerebrospinal fluid (CSF) and blood of 15 patients with essential hypertension were studied. The CSF and blood sampling was carried out after 7 days of a high salt intake (16-18 g/day) and after 7 days of a low salt intake (1-3 g/day). 2. Blood pressure and sodium concentrations in CSF and serum were significantly higher in the high salt period than the low salt period (CSF Na+ concentration: 147.7 +/- 0.4 mmol/L vs 145.3 +/- 0.5 mmol/L; P less than 0.001). Levels of CSF pressure and potassium or calcium concentrations were not different between the two periods. Plasma NA and plasma renin activity (PRA) were lower and CSF NA levels tended to be lower in the high salt period. 3. The levels and the changes in sodium and NA in CSF were not significantly different between the salt-sensitive (n = 8) and the non-salt-sensitive (n = 7) subjects, but the changes in plasma NA and PRA were smaller in the salt-sensitive subjects. 4. These results indicate that the sympathetic nervous system is less suppressed in salt-sensitive subjects during high salt intake. This may be due to altered neural responsiveness to sodium loading rather than being greater increases in sodium concentration in the central nervous system.     

PLASMA AND PITUITARY PROLACTIN AND BLOOD PRESSURE IN BROMOCRIPTINE-TREATED SPONTANEOUSLY HYPERTENSIVE AND WISTAR-KYOTO RATS

1. The effects on blood pressure (BP) and plasma and pituitary prolactin (PRL) of a 13 day intraperitoneal infusion of bromocriptine delivered by osmotic minipump were investigated in spontaneously hypertensive rats (SHR) and their normotensive controls, the Wistar-Kyoto rats (WKY). 2. In the SHR, a fall in BP which was steepest over the initial few days and sustained up to day 12 was observed in the bromocriptine-treated group compared with the lack of a change in BP observed in the vehicle-treated group. The plasma PRL level taken on day 13 was found to be significantly lower in the bromocriptine-treated group than in the vehicle-treated group. 3. In the WKY, bromocriptine had no significant effect on either BP or plasma PRL. 4. Pituitary PRL content was significantly lower in the SHR than in the WKY. The suppression by bromocriptine treatment was greater in the SHR than in the WKY. 5. These results provide further evidence for a central dopaminergic insufficiency in the SHR and raise the possibility that PRL may, either directly or indirectly by interacting with other factors in the SHR, influence BP.